openPR Logo
Press release

Neuroblastoma Drugs Market to Witness Huge Growth by 2031 - Cellectar Biosciences, INC, United Therapeutics Corporation, APEIRON Biologics AG.

08-21-2024 10:39 AM CET | Health & Medicine

Press release from: DataM Intelligence 4market Research LLP

Neuroblastoma Drugs Market to Witness Huge Growth by 2031 -

DataM Intelligence has published a new research report on "Neuroblastoma Drugs Market Size 2024". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

Get a Free Sample Research PDF - https://datamintelligence.com/download-sample/neuroblastoma-drugs-market

The Neuroblastoma Drugs market report majorly focuses on market trends, historical growth rates, technologies, and the changing investment structure. Additionally, the report shows the latest market insights, increasing growth opportunities, business strategies, and growth plans adopted by major players. Moreover, it contains an analysis of current market dynamics, future developments, and Porter's Five Forces Analysis.

Neuroblastoma drugs are used to treat neuroblastoma, a cancer that commonly affects young children and originates in nerve cells. Treatment often involves a combination of chemotherapy drugs, such as cisplatin, etoposide, and cyclophosphamide, to kill cancer cells. Other therapies include immunotherapy with dinutuximab, targeted agents like retinoids (e.g., isotretinoin), and radiation therapy. These drugs aim to shrink tumors, control disease spread, and improve survival rates.

Forecast Growth Projected:

The Global Neuroblastoma Drugs Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

List of the Key Players in the Neuroblastoma Drugs Market:

Cellectar Biosciences, INC, United Therapeutics Corporation, APEIRON Biologics AG, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services, Inc, MacroGenics, Bristol-Myers Squibb Company, Eli Lilly and Company, Marsala Biotech Inc, Pfizer Inc.

Segment Covered in the Neuroblastoma Drugs Market:

By Drug Type: Dinutuximab, Cisplatin, Doxorubicin, Vincristine, Etoposide, Others.

By Distribution Channel: Hospital Pharmacies, Clinics, Cancer research institutes, Others.

Regional Analysis:

The global Neuroblastoma Drugs Market report focuses on six major regions: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa.

Get Customization in the report as per your requierments: https://datamintelligence.com/customize/neuroblastoma-drugs-market

Regional Analysis:

The global Neuroblastoma Drugs Market report focuses on six major regions: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa. The report offers detailed insight into new product launches, new technology evolutions, innovative services, and ongoing R&D. The report discusses a qualitative and quantitative market analysis, including PEST analysis, SWOT analysis, and Porter's five force analysis. The Neuroblastoma Drugs Market report also provides fundamental details such as raw material sources, distribution networks, methodologies, production capacities, industry supply chain, and product specifications.

Chapter Outline:

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: key insights, key emerging trends, etc.

Chapter 3: Manufacturers competitive analysis, detailed analysis of Neuroblastoma Drugs manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 5 & 6: Revenue of Neuroblastoma Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: The main points and conclusions of the report.

Get a Free Sample PDF copy of the report @ https://datamintelligence.com/download-sample/neuroblastoma-drugs-market

Read Latest Blog: https://www.datamintelligence.com/blogs/top-10-process-automation-companies-worldwide

Affiliate Marketing Request here: https://www.datamintelligence.com/affiliate-marketing

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Neuroblastoma Drugs Market to Witness Huge Growth by 2031 - Cellectar Biosciences, INC, United Therapeutics Corporation, APEIRON Biologics AG. here

News-ID: 3629331 • Views:

More Releases from DataM Intelligence 4market Research LLP

Graphite Electrode Market to Expand at 6.2% CAGR as EAF-Based Green Steel, UHP Electrode Demand & Asia-Pacific's 60%+ Share Reshape Steelmaking
Graphite Electrode Market to Expand at 6.2% CAGR as EAF-Based Green Steel, UHP E …
The Global Graphite Electrode Market reached USD 8.1 billion in 2022 and is expected to reach USD 13.0 billion by 2031 growing with a CAGR of 6.2% during the forecast period 2024-2031. , according to DataM Intelligence. United States: Recent Industry Developments ✅ In October 2025, GrafTech International Ltd. expanded its U.S. ultra-high-power graphite electrode production by 20% at its Ohio facilities, partnering with major steelmakers such as Nucor to support electric
Aluminium Casting Market Set to Soar at 5.3% CAGR Through 2032 Driven by Automotive Lightweighting, EV Expansion, and Aerospace Innovations
Aluminium Casting Market Set to Soar at 5.3% CAGR Through 2032 Driven by Automot …
The global aluminum casting market reached US$ 79.07 billion in 2023, rising to US$ 83.50 billion in 2024, and is expected to reach US$ 126.22 billion by 2032, growing at a CAGR of 5.3% from 2025 to 2032. according to DataM Intelligence. United States: Recent Industry Developments ✅ In October 2025, Alcoa Corporation expanded its U.S. high-pressure die casting capacity by 20% in Tennessee facilities, partnering with automotive OEMs like Ford to
Remote Infrastructure Management (RIM): Driving Operational Efficiency, Cybersecurity, and Scalability Across Hybrid and Cloud Environments
Remote Infrastructure Management (RIM): Driving Operational Efficiency, Cybersec …
Remote Infrastructure Management (RIM) refers to the practice of managing and monitoring an organization's IT infrastructure such as servers, networks, storage systems, and endpoints remotely using specialized tools and technologies. This includes activities like system monitoring, performance optimization, security management, patching, troubleshooting, and backup management, all handled without requiring on-site presence. Download Exclusive Sample: https://www.datamintelligence.com/download-sample/remote-infrastructure-management-market?rk RIM helps organizations ensure business continuity, minimize downtime, and optimize operational efficiency. It is particularly valuable for
Surface Protection Films Market Growth: Self-Healing, Nanocoatings, and Smart Films Redefining Product Protection
Surface Protection Films Market Growth: Self-Healing, Nanocoatings, and Smart Fi …
Surface Protection Films (SPFs) are thin, flexible polymeric films applied to surfaces to safeguard them from scratches, dust, dirt, UV exposure, and minor impacts during manufacturing, storage, transportation, or installation. These films are widely used in industries such as electronics, automotive, construction, aerospace, furniture, and metal fabrication to preserve the aesthetic and functional quality of surfaces. Download Exclusive Sample: https://www.datamintelligence.com/download-sample/surface-protection-films-market?rk SPFs are typically made from materials like polyethylene (PE), polypropylene (PP), polyurethane

All 5 Releases


More Releases for Neuroblastoma

Pediatric Relapsed & Refractory Neuroblastoma Market Trades 2034
Market Overview The Pediatric Relapsed and Refractory Neuroblastoma Market is expanding as unmet needs remain high for children who fail first-line therapy or experience disease recurrence. Neuroblastoma, a rare pediatric cancer originating in nerve tissues, poses significant treatment challenges when it becomes resistant or relapses after conventional chemotherapy, surgery, and radiation. As a result, demand for novel immunotherapies, targeted biologics, CAR-T therapies, and precision medicine is accelerating globally. Improved survival outcomes,
Neuroblastoma Market Massive Growth opportunity Ahead
Neuroblastoma market Size, Status, and Forecast for the 2025-2034. In-depth research has been compiled to provide the most up-to-date information on key aspects of the worldwide market. This research report covers major aspects of the Neuroblastoma Market including drivers, restraints, historical and current trends, regulatory scenarios, and technological advancements. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). The
Pediatric Neuroblastoma Treatment Market - Redefining Possibilities: Advancement …
Newark, New Castle, USA: The "Pediatric Neuroblastoma Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Pediatric Neuroblastoma Treatment Market: https://www.growthplusreports.com/report/pediatric-neuroblastoma-treatment-market/7681 This latest report researches the industry structure,
Neuroblastoma Treatment Market Projected to Garner Significant Revenues by 2024
Neuroblastoma is the most common type of cancer in infants. The cancer is caused as a result of embryonal malignancy of sympathetic nervous system which arises from the neuroblasts. The cancer develops in the nerve tissues of adrenal, chest or spinal cord. Neuroblastoma is listed as a “rare disease” in the U.S. by the National Institute of Health (NIH), and Orphanet in Europe. The cancer is most prevalent in infants
Neuroblastoma Drugs Market Size, Share, Development by 2024
New report published by Global Info Research which offers insights on the Global Neuroblastoma Drugs market. Neuroblastoma (NB) is a type of cancer that forms in certain types of nerve tissue. It most frequently starts from one of the adrenal glands, but can also develop in the neck, chest, abdomen, or spine. Symptoms may include bone pain, a lump in the abdomen, neck, or chest, or a painless bluish lump under
04-14-2017 | Health & Medicine
TMR
Global Neuroblastoma Treatment Market: Latest Trends and Insights 2023
Neuroblastoma is the most common type of cancer in infants. The cancer is caused as a result of embryonal malignancy of sympathetic nervous system which arises from the neuroblasts. The cancer develops in the nerve tissues of adrenal, chest or spinal cord. Neuroblastoma is listed as a “rare disease” in the U.S. by the National Institute of Health (NIH), and Orphanet in Europe. The cancer is most prevalent in infants